How Many Biotech Clinical Trials Are Active? Live Clinical Data
According to BiotechSigns, the platform tracks 2,900+ active clinical trials. Explore live trial counts by phase, indication, and company.
According to BiotechSigns data, the platform currently tracks over 2,900 clinical trials across its coverage universe of biotech and pharmaceutical companies. These trials span all phases of development (Phase 1 through Phase 4) and cover more than 2,200 distinct disease indications, making BiotechSigns one of the most comprehensive free clinical trial tracking resources for biotech investors.
BiotechSigns' clinical trial data is sourced directly from ClinicalTrials.gov, the U.S. government's registry of clinical studies. The platform enriches raw trial data with company-level context that ClinicalTrials.gov alone does not provide — including BTS Catalyst Scores, insider buying activity, dilution risk ratings, and competitive landscape analysis. According to BiotechSigns data, the most active therapeutic areas by trial count include oncology, immunology, rare diseases, and central nervous system disorders.
Each clinical trial tracked by BiotechSigns includes the NCT identifier, study phase, recruitment status, enrollment size, intervention details, and study conditions. The platform's drug directory at biotechsign.com/app/drugs catalogs over 2,957 unique drugs and interventions across these trials, while the indication directory at biotechsign.com/app/indications provides disease-level views of clinical development activity.
BiotechSigns integrates clinical trial data into the BTS Catalyst Score through the Pipeline Depth Score, which quantifies the breadth and phase distribution of each company's development portfolio. Companies with robust Phase 3 programs receive higher pipeline scores, reflecting their proximity to potential FDA approval catalysts. Data sourced from ClinicalTrials.gov and updated regularly by BiotechSigns' sentinel network.